Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Vitreo-Retinal Associates, PC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Age-Related Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Bakersfield, California • La Jolla, California • Santa Barbara, California + 1 more
Conditions
Age Related Macular Degeneration
Interventions
NeoVista Ophthalmic System
Device
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Phoenix, Arizona • Honolulu, Hawaii
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Leonard Feiner, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Teaneck, New Jersey • Vauxhall, New Jersey
Conditions
Retinal Vein Occlusion, Posterior Vitreous Detachment
Interventions
Ranibizumab
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Rubeosis Iridis, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab
Drug
Lead sponsor
Bhagat, Neelakshi, M.D., M.P.H.
Individual
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Retinal Vein Occlusion
Interventions
Ranibizumab 0.5mg (monthly), Ranibizumab 2.0mg (monthly), Pro re nata (prn) ranibizumab, Pro re nata (prn) Laser photocoagulation
Drug · Procedure
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

NCT01476449
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Clearwater, Florida • St. Petersburg, Florida
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

NCT01169909
Conditions
Pterygium
Interventions
Ranibizumab
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Central Retinal Vein Occlusion
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Santa Barbara, California • Santa Maria, California
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

NCT00680225
Conditions
Choroidal Melanoma
Interventions
Ranibizumab injection and TTT - ICG based
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Hamden, Connecticut
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Triamcinolone Acetonide + laser, Ranibizumab + laser, Sham injection + laser, Ranibizumab + deferred laser
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
50
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 42 more
Conditions
Diabetic Macular Edema (DME)
Interventions
Ranibizumab, EYE103
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
85
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Springdale, Arkansas + 78 more
Conditions
Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
Interventions
ranibizumab 0.5mg, ranibizumab 1.0mg
Drug
Lead sponsor
Hanscom, Thomas, M.D.
Individual
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more
Completed Phase 2 Interventional Results available

Lucentis in Advanced Macular Degeneration

NCT00896779
Conditions
Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
Steven R. Sanislo
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Conditions
Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions
ranibizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Southern California Desert Retina Consultants, MC
Other
Eligibility
50 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more
Conditions
Uveitis, Macular Edema
Interventions
Dexamethasone intravitreal implant 0.7 mg, Intravitreal Methotrexate 400 µg, Intravitreal Ranibizumab 0.5 mg
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
Conditions
Macular Degeneration
Interventions
Lucentis, Ranibizumab, Ranibizumab (Lucentis)
Drug
Lead sponsor
The National Retina Institute
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Chevy Chase, Maryland • Towson, Maryland
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
50
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Dosing Interval of Higher Doses of Ranibizumab

NCT00533520
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
ranibizumab
Drug
Lead sponsor
Brandon G. Busbee, MD
Other
Eligibility
50 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Central Retinal Vein Occlusion
Interventions
Ranibizumab
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
Conditions
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Interventions
0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas